Galimedix Therapeutics Presents Data Showing Safety, Tolerability and Potential for Efficacy of Its Investigational Eyedrops Containing GAL-101 at Glaucoma 360 Conference
February 06, 2019 09:35 ET
|
Galimedix
KENSINGTON, Md. and SHORASHIM, Israel, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, presented an...
Galimedix Therapeutics to Participate in the 8th Annual Glaucoma 360 Conference
January 29, 2019 08:30 ET
|
Galimedix
KENSINGTON, Md. and SHORASHIM, Israel, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today announced its...
Galimedix Therapeutics Appoints Industry Veteran, Hermann Russ, M.D., Ph.D., Chief Scientific Officer
December 11, 2018 08:30 ET
|
Galimedix
KENSINGTON, Md. and SHORASHIM, Israel, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, announced the...
New In Vitro Study Demonstrates Galimedix Therapeutics’ Investigational Compound MRZ-99030 Neutralizes the Reproduction of Misfolded Amyloid-Beta, Thereby Potentially Reducing Synaptotoxic Effects
November 08, 2018 08:30 ET
|
Galimedix
“Hot Topics” Poster at Society for Neuroscience Conference Suggests Even Highly Diluted Concentrations of MRZ-99030 Prevented Formation of Toxic Amyloid Beta Oligomers KENSINGTON, Md. and SHORASHIM,...
New In Vitro Study Demonstrates Galimedix Therapeutics’ Investigational Compound MRZ-99030 Neutralizes the Reproduction of Misfolded Amyloid-Beta, Thereby Potentially Reducing Synaptotoxic Effects
November 08, 2018 03:30 ET
|
Galimedix
“Hot Topics” Poster at Society for Neuroscience Conference Suggests Even Highly Diluted Concentrations of MRZ-99030 Prevented Formation of Toxic Amyloid Beta Oligomers KENSINGTON, Md. and SHORASHIM,...